Machine Learning as a Multifaceted Tool in Glomerular Diseases: Beyond Risk Prediction

Glomerular diseases are a heterogeneous group of disorders with highly variable clinical outcomes, ranging from spontaneous remission to progressive kidney failure. Traditional prognostic tools, including proteinuria, serum creatinine, and semiquantitative histopathologic scoring, capture only part of this complexity. In particular, they often reduce longitudinal patient data to static baseline measurements, discarding valuable information about disease trajectories, rate of change, and temporal variability. Machine learning (ML) has emerged as a promising analytical framework capable of addressing these limitations by processing time-series data, modeling nonlinear relationships, integrating multimodal data, and generating individualized risk estimates.

This review introduces fundamental ML paradigms relevant to nephrology, including supervised learning, unsupervised learning, reinforcement learning, and deep learning. A practical ML pipeline for clinical application is proposed, and key data sources that power modern models are introduced. Current clinical applications of ML in glomerular disease are highlighted, including digital pathology for automated histologic assessment, data-driven phenotyping to identify disease subtypes, improved diagnostic differentiation, and enhanced prediction of prognosis and treatment response. Lessons learned from clinical deployment failures, key challenges, ethical considerations, and future directions are also discussed.

ML enables deeper phenotyping and more accurate risk stratification by capturing complex nonlinear patterns in multimodal data that traditional methods cannot. Current applications span digital pathology, diagnostic support, prognostic modeling, and treatment-response prediction, with some tools now incorporated in clinical guidelines. Successful clinical translation requires diverse training data, rigorous external validation, interpretable model architectures, and ongoing collaboration between data scientists, clinicians, and regulators. ML augments, not replaces, clinical expertise - maximizing value from each patient encounter and biopsy specimen to improve individualized care and outcomes.